Strategic partnerships Leverage Entero Therapeutics' focus on GI diseases and its two proprietary technologies to pursue co-development or licensing deals with pharma companies specializing in celiac disease, cystic fibrosis related malabsorption, and inflammatory GI conditions.

Clinical stage leverage Target mid-to-late stage pharmaceutical and biotech firms seeking to augment their portfolios with first-in-class or near-term assets such as latiglutenase and adrulipase, aligning with potential milestone-based collaborations.

AI and data center synergies Explore strategic investment or collaboration opportunities stemming from Entero's Grid AI Corp subsidiary to monetize AI infrastructure capabilities, creating cross-selling avenues with tech-enabled healthcare logistics and data management solutions.

Financial and funding readiness Position joint financing or equity-for-partnership structures given Entero’s current funding level and recent financing activity, appealing to banks and specialty investors looking for clinical-stage portfolios with clear near-term milestones.

Global clinical expansion Identify opportunities to expand clinical operations and trials via CROs and exploratory studies in leading GI markets, leveraging Entero’s multi-program pipeline (niclosamide and adrulipase) to broaden evidence generation for partner collaborations.